JP2015024986A - Solid preparations - Google Patents
Solid preparations Download PDFInfo
- Publication number
- JP2015024986A JP2015024986A JP2014117147A JP2014117147A JP2015024986A JP 2015024986 A JP2015024986 A JP 2015024986A JP 2014117147 A JP2014117147 A JP 2014117147A JP 2014117147 A JP2014117147 A JP 2014117147A JP 2015024986 A JP2015024986 A JP 2015024986A
- Authority
- JP
- Japan
- Prior art keywords
- menthol
- solid preparation
- tablet
- blended
- mass
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Landscapes
- Medicinal Preparation (AREA)
Abstract
【課題】昇華性成分であるメントールを配合しているにも拘わらず、針状(髭状)結晶や、該固形製剤を入れた保存用透明ガラス容器(瓶)の内面の曇りを生じることのないメントール配合固形製剤及びその製造方法を提供する。【解決手段】メントール及び該メントール配合の固形製剤に対して麻子仁を配合したことを特徴とする固形製剤。【選択図】なし[PROBLEMS] To produce needle-like (butterfly-like) crystals and fogging of the inner surface of a transparent glass container (bottle) for storage containing the solid preparation despite the incorporation of menthol, a sublimable component. A solid preparation containing no menthol and a method for producing the same are provided. SOLUTION: A solid preparation comprising menthol and blended with menthol in a solid preparation containing the menthol. [Selection figure] None
Description
本発明は、昇華性成分であるメントールを配合した固形製剤に関する。 The present invention relates to a solid preparation containing menthol, which is a sublimable component.
メントールは昇華性を有し、固形製剤中にメントールを配合すると、ウィスカーと呼ばれる、錠剤表面の針状(髭状)結晶の発生や保存容器である透明ガラス瓶の内側が曇る等の弊害を生じ、商品価値の低下を招来することが知られていた(非特許文献1参照)。 Menthol has sublimation properties, and when menthol is blended into a solid preparation, whisker, the occurrence of needle-like (wax-like) crystals on the tablet surface and the inside of a transparent glass bottle that is a storage container become cloudy, It has been known to cause a decline in commercial value (see Non-Patent Document 1).
これを防止するために例えば錠剤では糖衣コーティングを施す方法等が提供されているが(特許文献1参照)、薄層糖衣とはいえ、製造時間やコスト面での不利は否めない。 In order to prevent this, for example, a tablet is provided with a sugar coating method (see Patent Document 1). However, although it is a thin-layer sugar coating, disadvantages in terms of manufacturing time and cost cannot be denied.
よって、より簡便でより効果的なメントールの昇華性抑制技術の開発が希求されていた。 Therefore, there has been a demand for the development of a simpler and more effective menthol sublimation suppression technique.
そこで、本発明は、昇華性成分であるメントールを配合しているにも拘わらず、ウィスカーと呼ばれる、針状(髭状)結晶や保存容器である透明ガラス瓶の内面の曇りを生じないメントール配合固形製剤及びその製造方法を提供することを課題とする。 Therefore, the present invention is a menthol-containing solid that does not cause fogging of the inner surface of a transparent glass bottle called a whisker, which is called a whisker, although it contains menthol, which is a sublimable component. It is an object to provide a preparation and a method for producing the same.
本発明者らは、上記課題を解決すべく鋭意検討を行った結果、メントールを配合した固形製剤に麻子仁を配合することにより、メントールに起因する、固形製剤表面の針状(髭状)結晶や該固形製剤を入れた保存用透明ガラス容器(瓶)の内面の曇りを生じないことを見出した。 As a result of intensive studies to solve the above-mentioned problems, the present inventors have formulated needle-shaped (bowl-like) crystals on the surface of a solid preparation resulting from menthol by blending aspen into a solid preparation containing menthol. It was also found that no fogging occurred on the inner surface of a transparent glass container (bottle) for storage containing the solid preparation.
かかる知見により得られた本発明の態様は次のとおりである。
(1)メントール及び麻子仁を配合したことを特徴とする固形製剤。
(2)メントールの含有量が製剤全体の0.09〜5.6質量%である前記(1)の固形製剤。
(3)メントールの1質量部に対して11質量部以上の麻子仁を配合した前記(1)又は(2)の固形製剤。
(4)錠剤であることを特徴とする前記(1)〜(3)の固形製剤。
(5)麻子仁を造粒して得られた顆粒にメントールを添加・混合し、該顆粒を圧縮成形して得られる錠剤であることを特徴とする前記(1)〜(3)に記載の固形製剤。
The embodiments of the present invention obtained from such findings are as follows.
(1) A solid preparation characterized by blending menthol and asakojin.
(2) The solid preparation of (1), wherein the content of menthol is 0.09 to 5.6% by mass of the whole preparation.
(3) The solid preparation according to (1) or (2) above, wherein 11 parts by mass or more of asakojin is blended with respect to 1 part by mass of menthol.
(4) The solid preparation of (1) to (3) above, which is a tablet.
(5) The tablet according to any one of (1) to (3) above, wherein the tablet is obtained by adding and mixing menthol to granule obtained by granulating asakojin and compressing the granule. Solid formulation.
本発明により、メントールの昇華性を簡易に抑制し、針状(髭状)結晶や、該固形製剤を入れた保存用透明ガラス容器(瓶)の内面の曇りを生じることのないメントール配合製剤を提供することが可能となった。 According to the present invention, a menthol blended preparation that easily suppresses the sublimability of menthol and does not cause clouding of the inner surface of a transparent glass container (bottle) for storage containing needle-like (fungus-like) crystals or the solid preparation. It became possible to provide.
「メントール」とは、2-イソプロピル-5-メチルシクロヘキサノールであり、本発明においてはl体、dl体の何れであってもよく、メントールを含有するもの(ハッカ油等)であってもよい。 “Menthol” is 2-isopropyl-5-methylcyclohexanol. In the present invention, it may be either l-form or dl-form, and may contain menthol (such as peppermint oil). .
メントールの配合(含有)量は、好ましくは製剤中0.09〜5.6質量%である。 The amount (containing) of menthol is preferably 0.09 to 5.6% by mass in the preparation.
「麻子仁(マシニン)」とは、アサCannabis sativa Linne(Moraceae)の果実であり、潤腸通便作用を有する生薬として知られている。 “Mashinin” is a fruit of Asa Cannabis sativa Linne (Moraceae), and is known as a herbal medicine having an intestinal stool effect.
麻子仁の配合(含有)量は、メントールの1質量部に対して11質量部以上が好ましく、より好ましくは30質量部以上である。 The blending (content) amount of Asakojin is preferably 11 parts by mass or more, more preferably 30 parts by mass or more with respect to 1 part by mass of menthol.
本発明の固形製剤は、錠剤、散剤、顆粒剤、カプセル剤、丸剤等が挙げられるが、特に錠剤の場合にウィスカー発生の課題が顕著に現れることから本発明の意義は大きい。 Examples of the solid preparation of the present invention include tablets, powders, granules, capsules, pills, and the like, but since the problem of whisker generation appears particularly in the case of tablets, the significance of the present invention is great.
固形製剤が錠剤である場合は、例えば、メントール、該メントールの昇華を抑制するに足る量以上の麻子仁、その他必要に応じて他の有効成分や添加剤・賦形剤等を混合し、必要に応じて造粒し、打錠機等を用いて圧縮成形することによって得られるが、まず、麻子仁を配合した粉体を造粒し、得られた麻子仁配合顆粒に、メントールを含む粉体を添加・混合して、該メントール及び麻子仁配合顆粒を圧縮成形することによって得るのが好ましい。 When the solid preparation is a tablet, for example, menthol, assortment of makojin in an amount sufficient to suppress sublimation of the menthol, and other active ingredients, additives / excipients, etc. are mixed as necessary. It is obtained by granulating according to the conditions and compression-molding using a tableting machine, etc., but first, a powder blended with mashinjin is granulated, and then the powder containing menthol in the resulting blended granule It is preferable to obtain by adding and mixing the body, and compression-molding the menthol and hemp seed blended granules.
固形製剤には、メントール及び麻子仁を配合する他、他の公知の有効成分及び添加剤・賦形剤等を本発明の効果を損なわない範囲で配合することができる。 In addition to blending menthol and aspen, other known active ingredients, additives / excipients, and the like can be blended in the solid preparation as long as the effects of the present invention are not impaired.
固形製剤は、メントール、該メントールの昇華を抑制するに足る量以上の麻子仁、その他必要に応じて他の有効成分や添加剤・賦形剤等を混合して得られる。必要に応じて造粒し、打錠機等を用いて圧縮成形してもよい。 The solid preparation can be obtained by mixing menthol, an amount of makijin that is sufficient to suppress sublimation of the menthol, and other active ingredients, additives / excipients and the like as required. If necessary, it may be granulated and compression-molded using a tableting machine or the like.
以下に、実施例、比較例及び試験例を挙げ、本発明を更に詳細に説明する。 Hereinafter, the present invention will be described in more detail with reference to Examples, Comparative Examples and Test Examples.
実施例1
まず、表1の造粒用粉末として挙げられた麻子仁から乳糖水和物までの成分を秤量後混合して麻子仁配合粉体を得た。該麻子仁配合粉体を、精製水を造粒溶剤として撹拌造粒機(バーチカル造粒機5L;パウレック社製)あるいは乳鉢で造粒し、乾燥して麻子仁配合顆粒を得た。該麻子仁配合顆粒に、後末添加として挙げられたクロスカルメロースナトリウムからリン酸水素カルシウムまでの成分を秤量後混合してメントール及び麻子仁配合顆粒を得た。該メントール及び麻子仁配合顆粒を、簡易錠剤成形機(HANDTAB−200;市橋精機社製)を用いて圧縮成形し、1錠質量392.5mgのメントール及び麻子仁配合錠剤を得た。
なお、実施例1の錠剤のメントール含有(配合)量は、錠剤中0.1質量%に相当する。
Example 1
First, the ingredients from assortment to lactose hydrate listed as granulating powders in Table 1 were weighed and mixed to obtain assortment powder. The powdered blend of aspen seeds was granulated with an agitation granulator (vertical granulator 5L; manufactured by POWREC) or a mortar using purified water as a granulating solvent, and dried to obtain granulated blended seeds. Ingredients from croscarmellose sodium to calcium hydrogen phosphate, which were listed as late additions, were weighed and mixed into the blended assorted granules to obtain menthol and blended granules. The granules containing menthol and asakojin were compression-molded using a simple tablet molding machine (HANDTAB-200; manufactured by Ichihashi Seiki Co., Ltd.) to obtain a tablet containing menthol and asakojin having a tablet weight of 392.5 mg.
The menthol content (formulation) in the tablet of Example 1 corresponds to 0.1% by mass in the tablet.
実施例2
実施例1の処方(組成)において、l-メントールを増量し、リン酸水素カルシウムを減量して、l-メントールの含有(配合)量が錠剤中1.0質量%になるように調整した他、実施例1に準拠し、1錠質量392.5mgのメントール及び麻子仁配合錠剤を得た。
Example 2
In the formulation (composition) of Example 1, the amount of l-menthol was increased, the amount of calcium hydrogen phosphate was decreased, and the content (formulation) of l-menthol was adjusted to 1.0% by mass in the tablet. In accordance with Example 1, a tablet containing menthol and hemp seed with a tablet mass of 392.5 mg was obtained.
実施例3
実施例1の処方(組成)において、l-メントールを増量し、リン酸水素カルシウムを減量して、l-メントールの含有(配合)量が錠剤中2.9質量%になるように調整した他、実施例1に準拠し、1錠質量392.5mgのメントール及び麻子仁配合錠剤を得た。
Example 3
In the formulation (composition) of Example 1, the amount of l-menthol was increased, the amount of calcium hydrogen phosphate was decreased, and the content (formulation) of l-menthol was adjusted to 2.9% by mass in the tablet. In accordance with Example 1, a tablet containing menthol and hemp seed with a tablet mass of 392.5 mg was obtained.
比較例1
実施例1と同量のメントールを配合し、麻子仁を除いた処方(組成)で1錠質量392.5mgのメントール配合錠剤を得た。
Comparative Example 1
The same amount of menthol as in Example 1 was blended, and a menthol-blended tablet having a tablet weight of 392.5 mg was obtained with a formulation (composition) excluding Asako.
比較例2
実施例2と同量のメントールを配合し、麻子仁を除いた処方(組成)で1錠質量418.8mgのメントール配合錠剤を得た。
Comparative Example 2
The same amount of menthol as in Example 2 was blended, and a menthol-blended tablet with a tablet mass of 418.8 mg was obtained with a formulation (composition) excluding Asakojin.
比較例3
実施例3と同量のメントールを配合し、麻子仁を除いた処方(組成)で1錠質量418.8mgのメントール配合錠剤を得た。
Comparative Example 3
The same amount of menthol as in Example 3 was blended, and a menthol blended tablet with a tablet mass of 418.8 mg was obtained with a formulation (composition) excluding Asakojin.
試験例1
[方法]
実施例1及び2並びに比較例1〜4で得られた錠剤それぞれ10錠をガラス白色瓶に入れて密栓し、65℃下に一晩保存した。そして、5℃で1日保存した後にウィスカーの発生状況を目視で確認した。
結果を表1に示した。
なお、評価基準は次のとおりである。
ウィスカーの発生なし:−,ウィスカーの発生あり:+
[結果]
表1より、メントールを含有し、麻子仁を配合していない比較例1、2及び3ではウィスカーの発生が確認された。これに対して、麻子仁を配合した実施例1、2及び3ではウィスカーの発生を抑制できることが確認された。
以上により、固形製剤中に配合したメントールに起因するウィスカーの発生を抑制するには、麻子仁を配合すると効果があることがわかった。
Test example 1
[Method]
Ten tablets each obtained in Examples 1 and 2 and Comparative Examples 1 to 4 were placed in a glass white bottle, sealed, and stored overnight at 65 ° C. Then, after storage at 5 ° C. for 1 day, the occurrence of whiskers was visually confirmed.
The results are shown in Table 1.
The evaluation criteria are as follows.
No whisker occurrence:-, whisker occurrence: +
[result]
From Table 1, the occurrence of whiskers was confirmed in Comparative Examples 1, 2 and 3 containing menthol and not blended with asako. On the other hand, it was confirmed that Examples 1, 2, and 3 containing Asako Jin can suppress the generation of whiskers.
From the above, it was found that blending makijin is effective in suppressing the occurrence of whiskers due to menthol blended in the solid preparation.
本発明により、メントールの昇華性を簡易に抑制し、針状(髭状)結晶や透明ガラス瓶の容器内に保存しても内面に曇りを生じないメントール配合固形製剤を提供することが可能となった。よって、より商品価値の高いメントール配合固形製剤の市販を通じて医薬品産業等の発展が期待される。 According to the present invention, it is possible to provide a menthol-containing solid preparation that easily suppresses the sublimability of menthol and does not cause fogging on the inner surface even when stored in a container of needle-like (basket-like) crystals or transparent glass bottles. It was. Therefore, development of the pharmaceutical industry and the like is expected through the marketing of menthol-containing solid preparations with higher commercial value.
Claims (5)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2014117147A JP2015024986A (en) | 2013-06-20 | 2014-06-06 | Solid preparations |
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2013129940 | 2013-06-20 | ||
JP2013129940 | 2013-06-20 | ||
JP2014117147A JP2015024986A (en) | 2013-06-20 | 2014-06-06 | Solid preparations |
Publications (1)
Publication Number | Publication Date |
---|---|
JP2015024986A true JP2015024986A (en) | 2015-02-05 |
Family
ID=52489947
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2014117147A Pending JP2015024986A (en) | 2013-06-20 | 2014-06-06 | Solid preparations |
Country Status (1)
Country | Link |
---|---|
JP (1) | JP2015024986A (en) |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9393279B2 (en) | 2011-02-11 | 2016-07-19 | Zx Pharma, Llc | Enteric coated multiparticulate controlled release peppermint oil composition and related methods |
US9572782B2 (en) | 2013-04-23 | 2017-02-21 | Zx Pharma, Llc | Enteric coated multiparticulate composition with proteinaceous subcoat |
US9668982B2 (en) | 2011-02-11 | 2017-06-06 | Zx Pharma, Llc | Preventing whisker growth from an L-menthol composition |
IT201800010262A1 (en) * | 2018-11-12 | 2020-05-12 | Kyvaris Pharma Srls | Formulation in macro-granules based on therapeutic cannabis and related production method |
US11779547B2 (en) | 2011-02-11 | 2023-10-10 | Société des Produits Nestlé S.A. | Multiparticulate L-menthol formulations and related methods |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1887334A (en) * | 2005-06-27 | 2007-01-03 | 成都康弘科技实业(集团)有限公司 | Cathartic medicine composition |
JP2009256265A (en) * | 2008-04-18 | 2009-11-05 | Eisai R & D Management Co Ltd | Colored solid preparation and its production method |
JP2012072190A (en) * | 2007-10-03 | 2012-04-12 | Asahi Group Holdings Ltd | Granule, tablet, and method for producing the same |
JP2012246257A (en) * | 2011-05-30 | 2012-12-13 | Shionogi & Co Ltd | Azabenzoxazole derivative having npyy5 receptor antagonism |
-
2014
- 2014-06-06 JP JP2014117147A patent/JP2015024986A/en active Pending
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1887334A (en) * | 2005-06-27 | 2007-01-03 | 成都康弘科技实业(集团)有限公司 | Cathartic medicine composition |
JP2012072190A (en) * | 2007-10-03 | 2012-04-12 | Asahi Group Holdings Ltd | Granule, tablet, and method for producing the same |
JP2009256265A (en) * | 2008-04-18 | 2009-11-05 | Eisai R & D Management Co Ltd | Colored solid preparation and its production method |
JP2012246257A (en) * | 2011-05-30 | 2012-12-13 | Shionogi & Co Ltd | Azabenzoxazole derivative having npyy5 receptor antagonism |
Cited By (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9393279B2 (en) | 2011-02-11 | 2016-07-19 | Zx Pharma, Llc | Enteric coated multiparticulate controlled release peppermint oil composition and related methods |
US9668982B2 (en) | 2011-02-11 | 2017-06-06 | Zx Pharma, Llc | Preventing whisker growth from an L-menthol composition |
US9707260B2 (en) | 2011-02-11 | 2017-07-18 | Zx Pharma, Llc | Enteric coated multiparticulate controlled release peppermint oil composition and related methods |
US11207276B2 (en) | 2011-02-11 | 2021-12-28 | Société des Produits Nestlé S.A. | Multiparticulate L-menthol formulations and related methods |
US11779547B2 (en) | 2011-02-11 | 2023-10-10 | Société des Produits Nestlé S.A. | Multiparticulate L-menthol formulations and related methods |
US9572782B2 (en) | 2013-04-23 | 2017-02-21 | Zx Pharma, Llc | Enteric coated multiparticulate composition with proteinaceous subcoat |
US9717696B2 (en) | 2013-04-23 | 2017-08-01 | ZxPharma, LLC | Enteric coated multiparticulate composition with proteinaceous coating for improved storage stability |
US10420730B2 (en) | 2013-04-23 | 2019-09-24 | Zx Pharma, Llc | L-menthol dosage forms having a proteinaceous coating for enhanced storage stability |
US11207273B2 (en) | 2013-04-23 | 2021-12-28 | Société des Produits Nestlé S.A. | Method of making an L-menthol dosage form |
US11826475B2 (en) | 2013-04-23 | 2023-11-28 | Société des Produits Nestlé S.A. | Enteric coated multiparticulate compositions with a proteinaceous subcoat |
IT201800010262A1 (en) * | 2018-11-12 | 2020-05-12 | Kyvaris Pharma Srls | Formulation in macro-granules based on therapeutic cannabis and related production method |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2015024986A (en) | Solid preparations | |
JP6662312B2 (en) | Solid composition | |
JP6701689B2 (en) | Solid composition | |
JP6580414B2 (en) | Herbal powder-containing tablets | |
JP2013216632A (en) | Pharmaceutical composition | |
JP2018104393A (en) | Solid preparation | |
CN103720669A (en) | Preparation method of compressible vitamin C granules | |
JP4122544B2 (en) | Tablet composition | |
WO2014013928A1 (en) | Stabilized solid preparation for internal use | |
JP6114573B2 (en) | Solid formulation containing loxoprofen sodium and antacid | |
JP6394142B2 (en) | Solid preparation | |
JP6051761B2 (en) | Solid preparation | |
JP2018177697A (en) | Solid composition | |
CN100404026C (en) | Oral medicinal composition containing fudosteine | |
JP6842970B2 (en) | Coenzyme Q10-containing preparation | |
JP4899304B2 (en) | Solid preparation for internal use containing ambroxol hydrochloride | |
JP2015229664A (en) | Meclizine-containing pharmaceutical composition | |
JP6668706B2 (en) | Solid composition | |
JP6439503B2 (en) | Solid preparation | |
CN102885804A (en) | Dopamine prodrug composition and preparation method thereof | |
JP7556178B1 (en) | Oral Formulations | |
JP7094563B2 (en) | Tablets, their manufacturing methods, and powders for tableting | |
JP6379700B2 (en) | tablet | |
JP2017078051A (en) | Pharmaceutical composition | |
JP2016020331A (en) | Solid preparation |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20170516 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20180109 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20180126 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20180424 |